Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2023-07-10 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - LCT 6 pages 27.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It does not contain financial statements, management discussion, or audit information. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement of a report but a substantive filing about capital changes.
2023-07-10 English
Application for quotation of securities - LCT 6 pages 27.8KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX by Living Cell Technologies Limited. It details the number and type of securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document references previous announcements (Appendix 3B) related to the securities issuance. This is a formal announcement related to capital market activities, specifically the quotation of new securities following a prior issue. It is not a financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) as it concerns updates on company fundraising and capital structure changes.
2023-07-10 English
Notification regarding unquoted securities - LCT 5 pages 26.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities by Living Cell Technologies Limited. It includes specifics such as the number of securities issued, issue date, issue price, and references to previous Appendix 3B announcements. The content focuses on the issuance of securities and capital changes rather than financial results, management changes, or other report types. The document is about a capital event involving securities issuance, which aligns with the 'Share Issue/Capital Change' category. The document length is about 4848 characters, which is sufficient to contain substantive details of the issuance rather than just an announcement of a report publication or a brief notice. Therefore, the appropriate classification is 'SHA' for Share Issue/Capital Change.
2023-07-10 English
Name and Branding Change 2 pages 125.2KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Living Cell Technologies Limited regarding a proposed company name change to Algorae Pharmaceuticals Limited. It mentions seeking shareholder approval at an upcoming extraordinary general meeting (EGM) planned for September 2023. The content focuses on the intention to rebrand and the procedural steps to be taken, without providing any financial data, detailed reports, or regulatory filings. The document is approximately 4970 characters, which is relatively short and primarily serves as a notification of a corporate action to be voted on by shareholders. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories such as management changes, capital updates, or financial reports.
2023-07-10 English
Proposed issue of securities - LCT 6 pages 30.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Living Cell Technologies Limited regarding a proposed issue of securities, including details about the number and type of securities, issue price, and regulatory compliance with ASX Listing Rules. It discusses a placement or other type of issue, conditions, timetable, fees, and other relevant information about the capital raising. There are no financial statements or detailed financial performance data, nor is it a report or transcript. The content clearly relates to a capital raising activity and changes in the company's capital structure. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support a confident classification.
2023-07-06 English
Proposed issue of securities - LCT 5 pages 26.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Living Cell Technologies Limited regarding a proposed issue of securities, specifically a placement of options. It details the number of securities, issue price, proposed issue date, and compliance with ASX listing rules. The content is focused on informing the market about the planned capital raising activity rather than presenting financial results or detailed reports. The document length is about 5632 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2023-07-06 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.